High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase II trial E2696

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1430-1436

  Kirkwood, J M ^a   Ibrahim, J ^a   Lawson, D H ^a   Atkins, M B ^a   Agarwala, S S ^a   Collins, K ^a   Mascari, R ^a   Morrissey, D M ^a   Chapman, P B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GANGLIOSIDE GM2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERANCE; FATIGUE; FEMALE; GRANULOCYTOPENIA; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL;

EID: 0035281923     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1430     Document Type: Article

References (10)

1. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
2. Studies of ganglioside fraction extracted from human malignant melanoma
3. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen
4. Cultured human melanocytes from black and white donors have different sunlight and ultraviolet A radiation sensitivities
5. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
6. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
7. Nonparametric estimation of incomplete observations
8. Regression models and life tables (with discussion)
9. Eastern Cooperative Oncology Group phase II randomized adjuvant trial of GM2-KLH + QS21 (GMK) vaccine ± high dose interferon-α 2b (HD IFN) in melanoma (MEL)
10. Relapse-free and overall survival are significantly prolonged by high-dose IFNα2b (HDI) compared to vaccine GM2-KLH with QS21 (GMK, Progenics) for high-risk resected stage IIB-III melanoma: Results of the intergroup phase III study E1694/S9512/C509801